Valuables | Development group (n = 231,363) | Validation group (n = 234,294) | ||
---|---|---|---|---|
Fulfilled 4/4 criteria | Did not fulfil criteria | Fulfilled 4/4 criteria | Did not fulfil criteria | |
(n = 63,528, 27.5%) | (n = 167,835, 72.5%) | (n = 65,104, 27.8%) | (n = 169,190, 72.2%) | |
Death, n | 63,417 | 154,012 | 64,967 | 154,687 |
Survival, n | 111 | 13,823 | 137 | 14,503 |
Survival rate (95% CI), % | 0.17 (0.15–0.21) | 8.24 (8.11–8.37) | 0.21 (0.18–0.25) | 8.57 (8.44–8.71) |
Sensitivity (95% CI), % | 29.2 | (29.0–29.4) | 29.6 | (29.4–29.8) |
Specificity (95% CI), % | 99.2 | (99.0–99.4) | 99.1 | (98.9–99.2) |
FPR (95% CI), % | 0.8 | (0.6–1.0) | 0.9 | (0.8–1.1) |
PPV (95% CI), % | 99.8 | (99.8–99.9) | 99.8 | (99.8–99.8) |
NPV (95% CI), % | 8.2 | (7.8–8.7) | 8.6 | (8.1–9.0) |
AUC (95% CI) | 0.904 | (0.902–0.905) | 0.889 | (0.887–0.891) |